000			a
999			_c20358 _d20358
003			OSt
005			20231219102925.0
008			231219b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_922466 _aSagar, Priyanka M.
245			_aOverview on analytical method development and validation for ertugliflozin in bulk and pharmaceutical dosage form
250			_aVol.13(3), Jul-Sep
260			_aRaipur _bAsian Pharma Press _c2023
300			_a222-228p.
520			_aDiabetes mellitus (DM) is a metabolic condition characterized by hyperglycemia, glycosuria, hyperglycemia, a negative nitrogen balance, and occasionally ketonemia. The type 2 sodium-dependent glucose co-transporters (SGLT), which are in charge of roughly 90% of the reabsorption of glucose from the glomerulus, are subject to strong and selective inhibition by ertugliflozin. This review's primary objective is to highlight the development and validation of analytical methods employing chromatographic and spectrophotometric techniques for ertugliflozin and combination products in bulk and pharmaceutical dose forms. RP-HPLC, UV, UPLC, and LC-MS techniques are used to determine the dosage of ertugliflozin when it is combined with metformin and sitagliptin. Spectrometric techniques for ertugliflozin in combination with metformin or sitagliptin contain parameters like solvent, wavelength, linearity, LOD, LOQ, etc., and HPLC methods for ertugliflozin in combination with metformin or sitagliptin include parameters like stationary phase, mobile phase, RT, detection wavelength, LOD, LOQ, etc. Discussions on the separation requirements for ertugliflozin in combination with metformin or sitagliptin are also addressed throughout this review.
650		0	_94639 _aPHARMACEUTICS
700			_922467 _aMankar, S. D.
773	0		_tAsian journal of pharmaceutical analysis _dRaipur A & V Publications _x2231-5667
856			_uhttps://ajpaonline.com/AbstractView.aspx?PID=2023-13-3-12 _yClick here
942			_2ddc _cAR